Alnylam's genetic disease drug succeeds key study, shares soar


Alnylam Pharmaceuticals Inc's drug to treat a rare genetic disease cleared a key study, moving the company closer to filing a marketing application for the drug, which is part of a new class of medicines that block disease-causing proteins. The company's shares soared as much as 38.4 percent to hit a 21-month high in morning trading on Wednesday.



from Biotech News